Disease & disorder

benign prostatic hyperplasia

MONDO:0010811

A non-cancerous nodular enlargement of the prostate gland. It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements. It is the most common urologic disorder in men, causing blockage of urine flow.

Clinical trials45
Recruiting7
Drug concepts studied4
Synonyms11

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

Benign prostatic hyperplasia

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems. The cause is unclear. Risk factors include a family history, obesity, type 2 diabetes, not enough exercise, and erectile dysfunction. Medications like pseudoephedrine, anticholinergics, and calcium channel blockers may worsen symptoms. The underlying mechanism involves the prostate pressing on the urethra thereby making it difficult to pass urine out of the bladder. Diagnosis is typically based on symptoms and examination after ruling out other possible causes. Treatment options include lifestyle changes, medications, a number of procedures, and surgery. In those with mild symptoms, weight loss, decreasing caffeine intake, and exercise are recommended, although the quality of the evidence for exercise is low. In those with more significant symptoms, medications may include alpha blockers such as terazosin or 5α-reductase inhibitors such as finasteride. Surgical removal of part of the prostate may be carried out in those who do not improve with other measures. Some studies have suggested that certain plant extracts may help mitigate symptoms of BPH. Examples include saw palmetto (Serenoa repens), stinging nettle (Urtica dioica) root, beta-sitosterol from African star grass (Hypoxis rooperi), and pygeum (extracted from th...

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base MorphologyNCT07694752 · 2026-07-15
RECRUITING
Spinal Versus General Anesthesia in Open Simple ProstatectomyNCT07643415 · 2026-04-29
RECRUITING
Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate CancerNCT07526675 · 2026-04-10
RECRUITING
Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.NCT05148156 · 2026-02-11
RECRUITING
Effect of Text Message Reminders on M-ISI Score After Prostate SurgeryNCT07071207 · 2025-09-15
RECRUITING
Sacral Neuromodulation for Male Overactive Bladder (MOAB)NCT06511141 · 2024-10-22
RECRUITING
Customized TULSA-PRO Ablation RegistryNCT05001477 · 2021-10-27
RECRUITING
Urinary Function and Multimorbidity Risks: A Longitudinal Study in Beijing Community-Dwelling ElderlyNCT07357714 · 2026-01-01
NOT_YET_RECRUITING
Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial)NCT07510685 · 2025-02-01
COMPLETED
The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis AnalysisNCT06589154 · 2024-10-10
COMPLETED
Outpatient Holmium LASER Enucleation of the Prostate: Benefit of MOSES(TM) 2.0 TechnologyNCT05768776 · 2023-06-28
ACTIVE_NOT_RECRUITING
Protein Kinase A in Prostate Cancer Tissue.NCT05460312 · 2023-03-01
UNKNOWN
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTsNCT06051942 · 2022-11-22
ACTIVE_NOT_RECRUITING
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery EmbolizationNCT04879940 · 2022-02-23
ACTIVE_NOT_RECRUITING
Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and PainNCT05803096 · 2021-12-12
COMPLETED
Intravesical Prostatic Protrusion Mimicking Urothelial Cell Carcinoma of the BladderNCT05077852 · 2021-12-12
UNKNOWN
Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.NCT04853914 · 2021-09-13
COMPLETED
Anti-Androgen Treatment for COVID-19NCT04446429 · 2020-10-21
COMPLETED
An Observational Study of Radial Access Embolization Procedures Using HydroPearl MicrospheresNCT04272216 · 2020-02-06
COMPLETED
Prostatic Urethral Lift (PUL) Pre-/Post-Radiation Treatment for Prostate CancerNCT03817216 · 2019-12-01
WITHDRAWN
The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in CystoscopyNCT03831321 · 2018-12-11
UNKNOWN
Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.NCT03630926 · 2018-10-16
UNKNOWN
Learning Curve of Digital Rectal Examination for Prostate Cancer Among InternshipNCT03479359 · 2018-02-26
UNKNOWN
MRI Guided Transurethral HIFU for Various Prostate DiseasesNCT03350529 · 2017-07-24
COMPLETED
Impact of Anticoagulants and Antiplatelets in Patients on Transurethral Resection of the ProstateNCT02822963 · 2016-03-01
WITHDRAWN
Serum Copeptin as a Predictor of the Risk of Hyponatremia After Transurethral ProstatectomyNCT03912766 · 2016-02-01
COMPLETED
Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem CellsNCT02425800 · 2015-07-28
COMPLETED
Evaluation of the Potential Association Between 5α-reductase Inhibitors Prescription and Occurrence of High Grade Prostate CancersNCT02873117 · 2014-12-01
COMPLETED
Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)NCT02167919 · 2014-07-01
COMPLETED
Robust Evaluation to Measure Improvements in Nonadherence From Low-cost DevicesNCT02015806 · 2014-03-01
COMPLETED
Application of DWI in Diagnosis of Prostate CancerNCT04962269 · 2013-06-12
COMPLETED
2013 Annual National Digital Rectal Exam (DRE) Day StudyNCT01886547 · 2013-06-01
COMPLETED
Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) LevelsNCT01678313 · 2012-08-01
COMPLETED
Effective Dose of Dexmedetomidine for Sedation in Patients Undergoing TURP/TURB Under Spinal Anesthesia With or Without Fentanyl by Age Groups: Randomized Comparative StudyNCT01665586 · 2012-03-01
COMPLETED
Choline Metabolites in People With Prostate Cancer and Those With Benign HyperplasiaNCT06380062 · 2012-01-12
COMPLETED
BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)NCT01520441 · 2011-03-01
WITHDRAWN
3D Recording of a Trans-rectal Prostate BiopsyNCT01314456 · 2011-03-01
UNKNOWN
Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy OutcomeNCT01826617 · 2010-12-01
COMPLETED
Korean Practice Patterns for Screening PCA(Prostate Cancer)NCT01371513 · 2010-05-01
COMPLETED
Economic Analyses of the REDUCE TrialNCT01337258 · 2010-01-01
COMPLETED

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.